Microarray-based gene expression studies in ovarian cancer

Cancer Control

Volumn 18, Issue 1, 2011, Pages 8-15

  Chon, Hye Sook ^a   Lancaster, Johnathan M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RESEARCH; CARCINOGENESIS; DNA MICROARRAY; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; MICROARRAY ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; REPRODUCIBILITY; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 78651491371     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481101800102     Document Type: Article

References (45)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Harries M, Kaye SB. Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs. 2001;10(9):1715-1724.
3. Kulesh DA, Clive DR, Zarlenga DS, et al. Identification of interferonmodulated proliferation-related cDNA sequences. Proc Natl Acad Sci U S A. 1987;84(23):8453-8457.
4. Lashkari DA, DeRisi JL, McCusker JH, et al. Yeast microarrays for genome wide parallel genetic and gene expression analysis. Proc Natl Acad Sci U S A. 1997;94(24):13057-13062.
5. Gilks CB, Vanderhyden BC, Zhu S, et al. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol. 2005;96(3):684-694.
6. Schaner ME, Ross DT, Ciaravino G, et al. Gene expression patterns in ovarian carcinomas. Mol Biol Cell. 2003;14(11):4376-4386.
7. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65(22):10602-10612.
8. Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst. 2001;93(19):1458-1464.
9. Spentzos D, Levine DA, Kolia S, et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005;23(31):7911-7918.
10. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004;22(23):4700-4710.
11. Dufva M. Fabrication of DNA microarray. Methods Mol Biol. 2009; 529:63-79.
12. Pease AC, Solas D, Sullivan EJ, et al. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci U S A. 1994;91(11):5022-5026.
13. Kuhn K, Baker SC, Chudin E, et al. A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res. 2004;14(11):2347-2356.
14. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359(19):1995-2004.
15. Chien J, Fan JB, Bell DA, et al. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol. 2009;114(1):3-11.
16. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29(4):365-371.
17. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006;24(9):1151-1161.
18. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286(5439):531-537.
19. Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol. 2001;159(4):1231-1238.
20. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62(16):4722-4729.
21. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422-6430.
22. Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009;7(6):618-630.
23. Rauh-Hain JA, Penson RT. Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer. 2008;18(5):934-936.
24. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160(4):1223-1228.
25. Anglesio MS, Arnold JM, George J, et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RASMAPK in ovarian serous low malignant potential tumors. Mol Cancer Res. 2008;6(11):1678-1690.
26. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198-5208.
27. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002;287(13):1671-1679.
28. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques. 2001;30(3):670-675.
29. Meinhold-Heerlein I, Bauerschlag D, Zhou Y, et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res. 2007;13(2 Pt 1):458-466.
30. Kim JH, Herlyn D, Wong KK, et al. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res. 2003;9(13):4782-4791.
31. Shvartsman HS, Lu KH, Lee J, et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003;90(1):44-50.
32. Huddleston HG, Wong KK, Welch WR, et al. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol. 2005;96(1):77-83.
33. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(21):7677-7682.
34. Berchuck A, Iversen ES, Luo J, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res. 2009;15(7):2448-2455.
35. Hartmann LC, Lu KH, Linette GP, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005;11(6):2149-2155.
36. Lancaster JM, Dressman HK, Whitaker RS, et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig. 2004;11(1):51-59.
37. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11(10):3686-3696.
38. Moss C, Kaye SB. Ovarian cancer: progress and continuing controversies in management. Eur J Cancer. 2002;38(13):1701-1707.
39. von Georgi R, Franke FE, Munstedt K. Influence of surgery and postoperative therapy and tumor characteristics on patient prognosis in advanced ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol. 2003;111(2):189-196.
40. Helleman J, Jansen MP, Span PN, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 2006;118(8):1963-1971.
41. Dressman HK, Berchuck A, Chan G, et al. An integrated genomicbased approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007;25(5):517-525.
42. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12(11):1294-1300.
43. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005;11(17):6300-6310.
44. Selvanayagam ZE, Cheung TH, Wei N, et al. Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet. 2004;154(1):63-66.
45. Roberts D, Schick J, Conway S, et al. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer. 2005;92(6):1149-1158.